Bio-Gene Technology has raised approximately A$3.275 million through its second tranche placement and share purchase plan underwriting, issuing over 51 million new shares and 69 million options to investors.
- Raised A$3.275 million before costs
- Issued 51.98 million fully paid shares
- Issued 69.22 million options exercisable at 3.5 cents
- Options expire 15 October 2027
- Placement approved by shareholders at August 2026 meeting
Completion of Capital Raise Strengthens Bio-Gene’s Balance Sheet
Bio-Gene Technology (ASX:BGT) has successfully closed the second tranche of its share placement and the underwriting of its share purchase plan (SPP), raising approximately A$3.275 million before costs. The company issued 51,980,000 fully paid ordinary shares to investors, following shareholder approval at an extraordinary general meeting in early August 2026.
Significant Option Issuance Accompanies Placement
Alongside the shares, Bio-Gene issued 69,221,150 options exercisable at 3.5 cents each, with an expiry date set for 15 October 2027. These options were granted to investors participating in the placement, the SPP underwriting, and the lead manager of the placement. This sizeable option pool offers investors a potential upside if the company’s share price appreciates above the exercise price within the next 15 months.
Regulatory Compliance and Disclosure
The company confirmed that the shares were issued without disclosure under Part 6D.2 of the Corporations Act 2001, relying on an exemption under section 708A(5)(e). Bio-Gene stated it has complied with all relevant provisions of the Act, including continuous disclosure obligations, and affirmed that no excluded information exists that would affect investors’ decisions. This transparency is critical for maintaining investor confidence during capital raises.
Capital Raise Supports Bio-Gene’s Growth Trajectory
This latest capital injection builds on prior funding rounds aimed at advancing Bio-Gene’s bio-insecticide products, such as Flavocide and Qcide, which target insecticide resistance with natural compounds. Previous raises have supported regulatory studies and scaling production, positioning Bio-Gene to meet growing global demand for safer pest management solutions. The fresh capital should provide additional runway and flexibility as the company progresses toward commercialisation milestones.
Bottom Line?
Bio-Gene’s completed placement and option issuance bolster its funding position, but investors should watch how the company deploys this capital amid ongoing regulatory and commercial milestones.
Questions in the middle?
- How will Bio-Gene allocate the proceeds from this placement to accelerate product development or market entry?
- What impact might the exercise of nearly 70 million options have on share dilution and future capital structure?
- Can Bio-Gene sustain investor interest and secure further funding as it approaches key regulatory submissions?